Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial.
Bernsdorf M, Ingvar C, Jörgensen L, Tuxen MK, Jakobsen EH, Saetersdal A, Kimper-Karl ML, Kroman N, Balslev E, Ejlertsen B. Bernsdorf M, et al. Among authors: tuxen mk. Breast Cancer Res Treat. 2011 Apr;126(2):463-70. doi: 10.1007/s10549-011-1352-2. Epub 2011 Jan 15. Breast Cancer Res Treat. 2011. PMID: 21234672 Clinical Trial.
[Treatment of elderly patients with breast cancer].
Paaschburg B, Pedersen A, Tuxen MK, Nielsen MM, Kroman N. Paaschburg B, et al. Among authors: tuxen mk. Ugeskr Laeger. 2008 Mar 31;170(14):1133-8. Ugeskr Laeger. 2008. PMID: 18405474 Review. Danish.
Adjuvant Cyclophosphamide and Docetaxel With or Without Epirubicin for Early TOP2A-Normal Breast Cancer: DBCG 07-READ, an Open-Label, Phase III, Randomized Trial.
Ejlertsen B, Tuxen MK, Jakobsen EH, Jensen MB, Knoop AS, Højris I, Ewertz M, Balslev E, Danø H, Vestlev PM, Kenholm J, Nielsen DL, Bechmann T, Andersson M, Cold S, Nielsen HM, Maae E, Carlsen D, Mouridsen HT. Ejlertsen B, et al. Among authors: tuxen mk. J Clin Oncol. 2017 Aug 10;35(23):2639-2646. doi: 10.1200/JCO.2017.72.3494. Epub 2017 Jun 29. J Clin Oncol. 2017. PMID: 28661759 Clinical Trial.
Is DBCG abreast of new developments?
Offersen BV, Ejlertsen B, Balslev E, Flyger H, Gerdes AM, Hansen MK, Hølmich LR, Jensen MB, Kristensen B, Laenkholm AV, Mouridsen HT, Nielsen MH, Overgaard J, Tuxen M, Vejborg I, Christiansen P. Offersen BV, et al. Among authors: tuxen m. Acta Oncol. 2018 Jan;57(1):1-2. doi: 10.1080/0284186X.2017.1408960. Epub 2018 Jan 3. Acta Oncol. 2018. PMID: 29297250 No abstract available.
A randomised study of tailored toxicity-based dosage of fluorouracil-epirubicin-cyclophosphamide chemotherapy for early breast cancer (SBG 2000-1).
Lindman H, Andersson M, Ahlgren J, Balslev E, Sverrisdottir A, Holmberg SB, Bengtsson NO, Jacobsen EH, Jensen AB, Hansen J, Tuxen MK, Malmberg L, Villman K, Anderson H, Ejlertsen B, Bergh J, Blomqvist C; Swedish Breast Cancer Group (SweBCG), the Danish Breast Cancer Group (DBCG) and the Scandinavian Breast Cancer Group (SBG). Lindman H, et al. Among authors: tuxen mk. Eur J Cancer. 2018 May;94:79-86. doi: 10.1016/j.ejca.2018.02.016. Epub 2018 Mar 20. Eur J Cancer. 2018. PMID: 29547834 Clinical Trial.
Physical deterioration and adaptive recovery in physically inactive breast cancer patients during adjuvant chemotherapy: a randomised controlled trial.
Møller T, Andersen C, Lillelund C, Bloomquist K, Christensen KB, Ejlertsen B, Tuxen M, Oturai P, Breitenstein U, Kolind C, Travis P, Bjerg T, Rørth M, Adamsen L. Møller T, et al. Sci Rep. 2020 Jun 16;10(1):9710. doi: 10.1038/s41598-020-66513-9. Sci Rep. 2020. PMID: 32546796 Free PMC article. Clinical Trial.
39 results